Sustanon 350 350mg/ml 10ml Vial by Dragon-Pharma

Usage

1. Inspect the vial.: Confirm the Dragon-Pharma hologram seal is intact and the authenticity code on the label is unscratched before the first draw — counterfeits have been identified in the injectable testosterone market.
2. Prepare peptide vials first.: Reconstitute lyophilised peptides (e.g., Ipamorelin, CJC-1295) with bacteriostatic water per manufacturer instructions and load into insulin syringes; handle Sustanon 350 separately to avoid cross-contamination of oil and aqueous vehicles.
3. Draw Sustanon 350 with a 21–23 G needle.: Wipe the rubber septum with an alcohol swab, insert the draw needle, and aspirate the required volume; at 350 mg/ml, 1.0 ml delivers 350 mg. Switch to a 23–25 G needle for intramuscular injection.
4. Select an intramuscular site: — gluteus maximus, vastus lateralis, or deltoid — and rotate sites across the twice-weekly injection schedule to minimise local tissue accumulation.
5. Administer peptide subcutaneous injections: on the same day or at scheduled intervals (morning/pre-sleep); subcutaneous and intramuscular routes do not interfere with each other when administered at separate anatomical locations.
6. Log every injection.: Record vial batch number, draw volume, injection site, and date alongside peptide doses to track combined protocol adherence and enable accurate interpretation of mid-cycle bloodwork.

Warnings

Frequently asked questions

Which peptides are most commonly combined with Sustanon 350 in anabolic protocols?

GHRP-2, GHRP-6, Ipamorelin, and CJC-1295 are the most frequently co-administered peptides with multi-ester testosterone blends like Sustanon 350. These growth hormone secretagogues amplify GH pulse amplitude and raise systemic IGF-1; the sustained androgenic baseline delivered by Sustanon 350's four-ester profile ensures that skeletal muscle androgen receptors remain occupied throughout each peptide dosing cycle, maximising the combined anabolic output.

How does the four-ester profile of Sustanon 350 complement the dosing schedule of twice-daily peptides?

Twice-daily peptide administration — typical for GHRP/CJC-1295 combinations — generates GH pulses every 8–12 hours; each pulse acts on muscle tissue that requires a stable androgenic environment to respond fully. Sustanon 350's decanoate fraction maintains serum testosterone above baseline for up to 14–21 days from a single injection, meaning no androgenic trough exists between peptide doses. This eliminates the suppressed-androgen windows that appear when short-ester testosterone is used alongside peptides.

What injection frequency is recommended when stacking Sustanon 350 with Ipamorelin and CJC-1295?

Twice-weekly Sustanon 350 injections — for example Monday and Thursday — are sufficient to maintain stable serum testosterone when co-administering Ipamorelin at 200–300 mcg and CJC-1295 at 100 mcg per subcutaneous injection, two to three times daily. The isocaproate and decanoate esters bridge the 3–4 day gap between Sustanon injections, so the androgenic substrate supporting IGF-1-driven anabolism remains uninterrupted throughout the peptide cycle.

How should the 10 ml Sustanon 350 vial be stored after the first draw, and how many doses does it contain?

After first puncture, store the vial at room temperature (15–25 °C) away from direct light; refrigeration is not required but is acceptable. At a typical twice-weekly dose of 350 mg (1 ml), one 10 ml vial contains exactly 10 full 1 ml doses — a five-week supply at that frequency. Use a fresh 21–23 gauge needle for each draw to preserve stopper integrity and maintain sterility across the vial's lifespan.

Can insulin syringes be used to draw Sustanon 350 from the vial, and what dose increments does that allow?

Standard 1 ml insulin-compatible syringes can be used for drawing Sustanon 350, though a larger gauge needle (21–23 G) is recommended for aspiration given the oil-based vehicle, with gauge downsizing to 25 G for injection if preferred. At 350 mg/ml, each 0.1 ml graduation on a 1 ml syringe delivers exactly 35 mg of testosterone ester blend, enabling clean dose increments of 35 mg, 70 mg, 105 mg, or 175 mg without estimation — a precision advantage for peptide-combination protocols where weekly testosterone is carefully titrated. (2) angle_used

Manufacturer

Dragon-Pharma's approach to product authentication for Sustanon 350 centres on a layered verification system that allows distributors, clinics, and end users to independently confirm product legitimacy before administration. Each 10 ml vial carries a unique alphanumeric authenticity code concealed beneath a scratch-off panel on the label; entering this code on Dragon-Pharma's official verification portal returns batch-specific production data — a direct traceability link between the physical vial in the user's hand and the laboratory records generated at the time of manufacture. The holographic security seal applied to the vial cap is produced using a substrate that cannot be separated cleanly from the aluminium crimp without visible damage, making re-sealing of tampered vials immediately apparent on inspection. This dual-layer system — digital code verification plus physical hologram integrity — is particularly relevant for Sustanon 350, a product in a concentration bracket (350 mg/ml) that has attracted counterfeit activity; the authentication infrastructure provides a checkpoint that commodity-fill operations cannot cost-effectively replicate. Batch HPLC and LAL release data are referenced within the verification portal response, meaning a user who confirms the hologram and enters the code simultaneously accesses analytical confirmation that the specific production lot met ester-fraction and endotoxin specifications before dispatch.